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Abstract
Objective:  We compared our institution’s initial experience with transrectal ultrasound-guided (TRUS)
prostate biopsies in a single arm prospective study to a historical cohort of finger guided (FG) biopsies. The
primary outcome measure was prostate cancer detection. We documented our findings on TRUS including
the findings of peripheral calcifications, hypoechoic lesions and capsular distortion and evaluated whether
these had any significance in prostate cancer detection.
Patients  and  methods: All patients presenting to our institution for prostate biopsy were included. Indica-
tions included raised PSA and/or abnormal DRE or other suspicion of prostate cancer. Data on 12-core
TRUS guided biopsies were prospectively collected and compared to a historical cohort of 6-core FG biop-
sies obtained from the pathology database of all prostate biopsies performed at Groote Schuur Hospital
within the study period.
Results:  One hundred and ninety-two patients were included in the TRUS group over a 25-month period
(2008–2010) and 262 FG biopsies were reviewed between 2006 and 2008. Abnormal DRE findings were
present in 56.2% of FG and 43.3% of TRUS biopsies. Histology was available in 97.8% of cases. The
incidence of prostate cancer was 42%. Malignant or suspicious histology was found in 45.6% of the FG
group compared to 48.6% in the TRUS group (p  = 0.27). In patients with a normal DRE there was a trend
that favoured TRUS for improved cancer detection, which is significant if the PSA was below 10 ng/mL.
Conclusion:  Our study did not show superiority of TRUS over FG biopsies except when the patient had a
low PSA (below 10 ng/mL) and a normal DRE. Systematic FG biopsies may be underutilised in the TRUS
era, and may be of benefit in patients presenting with a PSA over 10 ng/mL or an abnormal DRE. This may
be of value in a limited resource setting where access to TRUS is restricted.
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Introduction
Prostate cancer is the commonest malignancy among black males
in South Africa and the second commonest among white males
[1,2]. Although the incidence of prostate cancer is increasing in
the developed world, it remains under-diagnosed in the developing
world where it often presents late [3]. Biopsy of the prostate forms
the cornerstone in diagnosing and treating this disease. Historically,
needle biopsies of the prostate were performed either transrectally
or trans-perineally, with digital palpation of the gland and guidance
of the biopsy needle per rectum [4]. Three important developments
significantly changed the way the prostate cancer was diagnosed
in the early 1990s. Firstly, the adoption of a systematic rather than
random biopsy scheme as described by Hodge et al. [5]. Secondly,
the use of a biopsy gun as opposed to hand-operated Tru-cut needles
and thirdly, the advent of the transrectal ultrasound (TRUS) probe
enabling the clinician to visually guide the biopsy needle [6].
Over the last two decades, TRUS has become the gold standard
in performing prostate biopsies [7,8]. The initial work from Stan-
ford University demonstrated that TRUS biopsies diagnosed cancer
in 23 of 43 patients who had previous negative FG biopsies while
confirming previously digitally diagnosed cancer in 94% [9]. In a
further publication in the same journal, they showed that the yield of
prostate cancer was better with six systematic random biopsies than
FG biopsies of abnormal areas in the prostate [5]. The benefits of
ultrasound in guiding biopsy needles became more apparent as the
understanding of prostate anatomy and distribution of carcinoma
improved, assisted by McNeal’s description of the different zones
[10]. Since then much work has been done to determine the optimal
sites and numbers of prostate biopsies to maximise cancer detec-
tion of what remains a test with a significant sampling error. The
consensus today for initial biopsies is to use a minimum of 10–12
laterally directed biopsies from the peripheral zones with the use of
TRUS [11,12].
Our institution only acquired a transrectal ultrasound probe in 2008,
enabling us to perform TRUS guided biopsies. We prospectively col-
lected data on all TRUS guided prostate biopsies since the inception
of this service, using a standard proforma. The aim of this review
was to investigate our hypothesis that TRUS would increase the
yield of our prostate biopsies which were previously performed with
6 finger-guided (FG) cores. At the same time we wanted to evaluate
the extent to which the trainees were able to detect abnormalities
of the prostate on TRUS by recording the findings and correlating
them with cancer diagnoses.
Patients  and  methods
Approval was obtained from the Human Research Ethics Committee
of the Faculty of Health Sciences of the University of Cape Town.
The study population included all patients undergoing prostate
biopsy at our institution during the study period July 2006 to
February 2010. The first group was the FG biopsy group identified
from pathological records of needle biopsies of the prostate per-
formed in the time period immediately preceding the introduction
of TRUS at our hospital. The second group was the TRUS guided
biopsy group where data were prospectively collected since the start
of TRUS, on a standardised proforma at the time of biopsy and com-
bined with the histological findings. Only patients with complete
data sets were included in the study. Patients who underwent FG
biopsy during the TRUS period were excluded.
Clinical parameters included patient demographics including age,
reason for intervention (screening or symptoms), PSA value, and
clinical findings on DRE. DRE findings were classified from clinical
stage 1 to 4 according to the AJCC [13] staging system as found
on initial examination by a member of our Urology Department.
Absolute PSA values were recorded and subsequently subdivided
for the purposes of analyses into five groups: 0–4, 4–9.9, 10–19.9,
20–99.9 and >100 ng/mL.
TRUS was performed using a Toshiba diagnostic ultrasound
machine with a 7.5-MHz transrectal probe. Informed consent was
obtained and antibiotic prophylaxis administered orally 30 min
before the procedure. Local anaesthetic with intrarectal instilla-
tion of 20 mL 2% lignocaine jelly (Remicaine®, AI Generics, South
Africa) was used without periprostatic needle infiltration. The find-
ings on TRUS were documented for both the right and left lobe as
follows: the presence of hypoechoic areas and/or calcifications in
the periphery and the centre of the glands as well as the presence of
capsular distortion or the visualisation of a palpable irregularity.
The prostate gland was assessed in the axial plane where the
transverse and antero-posterior measurements were taken at the
point of maximum diameter, followed by a paramedian longitu-
dinal measurement in the sagittal plane. The volume was calculated
using a standard pre-programmed formula {π/6 ×  (transverse diam-
eter) ×  (antero-posterior diameter) ×  (superior–inferior diameter)}
based on an ellipsoid shape. The number of biopsies taken was doc-
umented prospectively in the TRUS group as either the routine 12
cores (2 cores from apex, mid-zone and base of prostate on the
periphery of either lobe) or the routine 12 cores plus additional
biopsies of suspicious areas (on ultrasound or digital examination).
Finger-guided biopsies were performed similarly to TRUS biopsies
using a Magnum Biopsy Instrument (C.R. Bard Inc., USA) with
18 G 25 cm Tru-cut needles. However, with finger-guided biopsies,
there was a maximum of 6 cores taken, 3 in each lateral lobe. Cores
were transferred in 2 specimen bottles for FG biopsies (left and right
lobes) and in 6 pots for TRUS biopsies (left and right apex, mid-zone
and base respectively).
Histological diagnoses were classified for the purposes of analysis
into benign if reported as normal prostate or benign prostatic hyper-
plasia or inflammation and as suspicious for malignancy if reported
as atypical, atypical small acinar proliferation (ASAP) or high grade
prostatic intraepithelial neoplasia (PIN). Gleason scores below 6
were classified as suspicious for malignancy and 6 and higher were
classified as malignant. To differentiate between negative biopsies
and those with pathological findings, patients with suspicious find-
ings were grouped together with the confirmed carcinomas.
Data were compiled using MicroSoft Excel® and statistical analysis
was performed by a biostatistician on Stata® software using the
Mann–Whitney U test for continuous variables and the Pearson’s
chi-squared test for categorical variables. A two-tailed p-value <0.05
was accepted as significant with a power of 80%.
Results
Over a 25-month period complete data sheets and pathology reports
were collected in 192 patients who underwent TRUS guided biopsies
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Table  1  Patient age, PSA and histology.
Finger guided
(n = 262)
TRUS guided
(n = 192)
p-Value
Age (mean ± SD) 68.4 ± 8.38 65.6 ± 7.87 0.0005
PSA
(median + IQR)
12 (8.8–52.8) 17.5 (6.5–24.2) 0.0001
DRE suspicious or
malignant
109/194 (56.2%) 78/180 (43.3%) 0.013
Benign histology 141 (54.4%) 94 (51.4%) 0.32
Malignant
histology
118 (45.6%) 89 (48.6%) 0.27
Gleason 6 31.3% 41.3%
Gleason 7 23.6% 30.7%
Gleason 8–10 45.3% 28%
at one hospital. The FG cohort comprised 262 patients over a 17-
month period preceding the start of TRUS guided biopsies.
Presenting  features
Patients in the TRUS group presented mostly with obstructive lower
urinary tract symptoms (65.2%) followed by referral with raised
PSA (21.5%), irritative or mixed lower urinary tract symptoms
(11.6%) and other symptoms (1.6%) such as haematuria or paralysis.
Patient age, presenting PSA value and clinical findings are presented
in Table 1 together with diagnosis of biopsy. Twenty-four patients
had a PSA value less than or equal to 4 and 399 patients a raised
PSA. In the FG and TRUS guided groups, the numbers of patients
with normal PSA (4 ng/mL and lower) were 12 (5%) and 12 (6.6%)
respectively, and with a raised PSA (more than 4 ng/mL) in 229
(95%) and 182 (93.4%) patients respectively. Statistically however,
when looking at the whole group, both age and PSA values were
significantly different.
Biopsies  performed
Biopsies were performed by an equal number of trainees [6] and
specialists [2] with similar level of experience in both finger guided
and TRUS guided biopsy groups, as shown in Table 2. Trainees
performed 97.9% of the TRUS guided biopsies during the study
period.
The number of biopsies taken differed in the two groups. In the finger
guided group the average number of cores was 6.24 (range 2–12).
In the TRUS group all but 15 patients had 12 or more cores, taken in
a systematic sextant fashion as described above. All but 3 patients
(due to technical failure of biopsy gun and patient being unable to
tolerate biopsy under local anaesthetic) who had less than 12 cores
taken with TRUS guidance had raised PSA above 50 ng/mL, with a
clinically malignant feeling prostate.
Figure  1  Histological findings in FG and TRUS guided groups.
Histology
Histology was available in 444 cases. The cancer detection rate was
42% overall, followed by benign prostatic hypertrophy, prostatitis
(mostly chronic) and atypia, ASAP and PIN. Results are shown in
Fig. 1. When comparing the FG with the TRUS group, there was no
difference in the cancer detection rate between the two groups. When
analysing the results according to DRE findings, more patients with
a normal feeling prostate in TRUS group had carcinoma (p  = 0.03).
Among the patients with an abnormal DRE and a PSA value of less
than 10 ng/mL, there was statistically an advantage in using TRUS
guided over FG biopsies.
Prostatitis was diagnosed in 69 (15.2%) patients, evenly distributed
between the two groups. The mean age (±SD) for patients with
histological evidence of prostatitis was 69.4 (±8.1) years with a
mean PSA of 16.9 ng/mL (IQR 7.1–19.8 ng/mL).
Eighty-eight patients had a palpable nodule on rectal examination
of which 48.9% were diagnosed with malignancy. When analysing
patients with an abnormal DRE in whom carcinoma was diagnosed,
the yield using TRUS was significantly better only if the PSA was
less the 10 ng/dL.
Features  identified  on  TRUS  of  the  prostate
The average size of prostates measured was 38.6 g. The findings
are presented in Table 3. The probability ratios (with a 95% con-
fidence interval) are presented to show the association between
TRUS findings and the incidence of malignancy on biopsy. Findings
included hypoechoic areas, peripheral calcifications, and a distorted
or irregular capsule with probability ratios of 1.34 (0.98–1.8), 0.9
(0.7–1.3) and 29.0 (4.0–210.5) respectively. The findings of hypoe-
choic areas or calcifications were therefore not associated with a
Table  2  Clinicians (A–P) performing prostate biopsies with finger guidance (FG) and transrectal ultrasound (TRUS) guidance.
Clinician
A B C D E F G H I J K L M N O P
FG (262) 10 53 27 24 74 24 18 6 3 7 10 5 0 0 0 0
TRUS (181) 0 0 3 0 31 15 15 3 11 4 0 30 21 13 30 5
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Table  3  Findings on transrectal ultrasound with histological
diagnosis.
TRUS findings Total Cancer No cancer
Capsule distorted 22 (13.0%) 21 1
Capsule intact 147 (87.0%) 50 97
Calcification PZ 108 (60.3%) 27 81
No calcification PZ 71 (39.7%) 21 50
Calcification centre 36 (21.3%) 17 19
No central calcif 133 (79.7%) 55 78
Hypoechoic PZ 100 (54.6%) 54 46
No hypoechoic PZ 83 (45.4%) 24 59
PZ, peripheral zone; calcif, calcification
higher probability of finding malignancy in the prostate biopsy.
However, when a distorted capsule was seen on TRUS, the probabil-
ity was at least 4 times higher, and on average 29 times higher than
the general population. In all the cases where capsular distortion or
irregularity was seen on TRUS, the DRE was also documented as
abnormal.
Discussion
Cancer  detection
The yield of prostate cancer overall was 42% in our study population
with no difference in the incidence between the FG and the TRUS
guided groups. This is in keeping with published figures, in spite of
the fact that there was, on average, double the number of biopsies
done in the TRUS group (12 cores) compared to the FG group (6
cores) [14,15]. This finding was contrary to our expectations, as we
believed TRUS not only to be sampling the prostate more precisely,
but also obtaining double the number of cores.
We also postulated that TRUS might be of more benefit where the
DRE was normal but when analysing these patients, there was a
trend favouring TRUS only if the PSA was lower than 20 ng/mL,
which was statistically significant only when the PSA was below
10 ng/mL. The subgroup of “normal” PSA below 4 ng/mL did not
reach significance, likely because of the small number of patients
in this group.
Digital  rectal  examination
The DRE was found to be abnormal in 50%. Among the patients who
had a normal DRE, 63 were diagnosed with carcinoma and these
patients were equally distributed between the FG and TRUS groups.
However, when stratifying these results according to PSA values as
shown in Figs. 2 and 3, this difference in diagnosis only approaches
statistical significance when the PSA value is less than 10 ng/mL.
This trend is maintained whether or not the diagnoses of PIN and
ASAP are included in the malignant group. This finding suggests
that TRUS biopsy is not superior to FG biopsies for patients with a
PSA value of more than 10 ng/mL, irrespective of the DRE findings.
According to our data, TRUS should be reserved for patients with
a normal DRE and a PSA value below 10 ng/mL.
Of note is the finding that patients were either screened with PSA
once they presented to the urological service with urinary symptoms
or were referred with a raised PSA. No patient was referred with
an abnormal DRE despite almost 50% of patients having a palpa-
ble nodule. We found that, in keeping with the literature, a nodule
Figure  2  Incidence of cancer in patients presenting with a benign
feeling prostate gland shown by PSA categories.
Figure  3  Incidence of cancer in patients presenting with an abnormal
DRE shown by PSA categories.
has a 49% chance of being malignant. In a resource limited setting
the performance of DRE is cost-effective and may prompt earlier
detection of disease and thus earlier referral for assessment.
Study  population
In our single arm prospective study of TRUS there were fewer biop-
sies performed over a 25-month period than was the case with the
17-month retrospective control group. Two factors can account for
this: excluded patients who underwent FG biopsies in the TRUS era,
and secondly, the increased time needed to perform TRUS compared
to FG biopsies. One weakness of this study is that our two study
groups were found to be statistically different in terms of age and
PSA value at presentation, even though our department’s clinical
indications for prostate biopsy have not changed over the course of
this study period. Although the mean patient age was significantly
higher in the FG biopsy group, the median PSA in this group was,
contrary to expectation, significantly lower than in the TRUS guided
biopsy group. This might be accounted for by the higher percent-
age of high Gleason grade cancers (Grade 8–10) in the retrospective
group. Whether the statistical difference in age and PSA is clinically
relevant, is debatable.
Number  of  biopsies
Although the current guidelines from leading professional
bodies [7,16] suggest at least 10-core biopsies, there is evidence
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to suggest that fewer cores are adequate [14,17]. The literature has
however shown that 6-core biopsies, in contrast to our findings,
are inferior to 10 and 12-core biopsies [18–20]. Although urol-
ogy trainees performed both FG and TRUS biopsies, with equal
experience in both approaches, the learning curve associated with
TRUS biopsy might impact the quality of the TRUS biopsies in our
study. Investigators have, however, found no learning curve associ-
ated with the procedure in studies that assessed the cancer detection
rate [21,22].
Finger  guided  targeted  biopsies
Initially the trials comparing FG with TRUS guided biopsies after
Hodge’s publication [5] consisted of small retrospective series,
showing conflicting results. Most trials investigating FG biopsies
involved only patients with abnormal DRE findings. Among these,
there is evidence to show that FG biopsies have a role to play in the
era of TRUS guided biopsies, especially in patients presenting with
an abnormal DRE [23–26].
Conclusion
While TRUS guided biopsies remain the gold standard, in centres
where TRUS is not available, a systematic finger guided biopsy
with a minimum of 6 cores, is a suitable alternative in patients who
present with an abnormal feeling prostate gland on DRE. It should
also be considered when there is a raised PSA, especially a PSA
level more than 10 ng/mL.
Our findings are limited by the study design, which due to its ret-
rospective nature limits the conclusions we can derive. However,
the benefits of FG biopsies are: that it is quick, requires fewer cores
and is readily available in resource limited settings where there is
not access to TRUS. In the absence of a prospective randomised
controlled trial directly comparing TRUS with FG biopsies, the role
of FG biopsies remains unproven.
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